Reviewer's report

Title: Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients

Version: 1 Date: 18 Sep 2017

Reviewer: Brandon Eilertson

Reviewer's report:
In this revised manuscript, Zhang et al describe in vitro antimicrobial susceptibilities for Gram negative bacteria causing intra-abdominal infection (IAI) at 21 different Chinese hospitals over the period 2012-2014. They describe high prevalence of ESBL production in both E. coli and Klebsiella pneumoniae in all years, but decreasing between 2012 and 2014. In the revised manuscript they now include a full description of clinically relevant resistance to carbapenems and fluoroquinolones. Prior major questions have been addressed including more information on agents likely to be used to treat ESBL Enterobacteriaceae infections of the abdomen and also a more complete discussion of how this may translate into clinic practice in China. Based on the revisions I recommend publication after addressing the minor comments below.

Minor Comments

1. Line 117 - Based on the common use of fluoroquinolone therapy at discharge for the treatment of IAI, your abstract should not that high prevalence of fluoroquinolone resistance may dictate a change in PO regimens in IAI in China

2. Line 171 - Crissum should be perianal

3. Line 217 - add space between from and 16.2

4. Lines 349-351 - this sentence is confusing. your data suggests CTX-M is not the main cause of ESBL resistance based on your low rates of cefoxitin susceptibility, better to cite
references showing that a diversity of enzymes circulate in china and that you did not investigate molecular mechanisms of resistance.

5. Lines 365 - should note implications of high prevalence FQ resistance on oral stepdown therapy

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal